PMID- 33460021 OWN - NLM STAT- MEDLINE DCOM- 20210823 LR - 20221207 IS - 1179-1888 (Electronic) IS - 1175-0561 (Print) IS - 1175-0561 (Linking) VI - 22 IP - 3 DP - 2021 May TI - HLA-Cw1 and Psoriasis. PG - 339-347 LID - 10.1007/s40257-020-00585-1 [doi] AB - Psoriasis is a chronic inflammatory skin condition with regional and ethnic differences in its prevalence and clinical manifestations. Human leukocyte antigen (HLA)-Cw6 is the disease allele conferring the greatest risk to psoriasis, but its prevalence is lower in Asian individuals. Recent studies have found associations between HLA-Cw1 and some Asian populations with psoriasis, especially Southern Chinese. HLA-Cw6 was associated with type I early-onset psoriasis, guttate psoriasis, Koebner phenomenon, and better response to methotrexate, interleukin (IL)-12/23, IL-17, and IL-23 targeting drugs. In contrast, HLA-Cw1 positivity has been associated with erythrodermic psoriasis, pustular psoriasis, and the axial type of psoriatic arthritis. Furthermore, HLA-Cw1 was more frequently associated with high-need patients who did not respond to conventional therapies. No known trigger factor nor autoantigen has been identified for HLA-Cw1 positivity. However, HLA-Cw1 has been linked to some viral agents. For example, cytotoxic T lymphocytes recognize multiple cytomegalovirus pp65-derived epitopes presented by HLA alleles, including HLA-C*01:02. In addition, cytomegalovirus can lead to severe exacerbation of psoriatic skin disease. The proposed interaction between viral infection, HLA-Cw1, and psoriasis is through the killer cell immunoglobulin-like receptors of natural killer cells. Given the diverse nature of psoriasis pathogenesis and the difference in HLA-Cw prevalence in different racial groups, more studies are needed to confirm the role of HLA-Cw1 in psoriasis. FAU - Huang, Yi-Wei AU - Huang YW AUID- ORCID: 0000-0001-7127-4242 AD - Department of Dermatology, National Taiwan University Hospital, No. 7 Chung San South Road, Taipei City, Taiwan. FAU - Tsai, Tsen-Fang AU - Tsai TF AUID- ORCID: 0000-0002-1498-1474 AD - Department of Dermatology, National Taiwan University Hospital, No. 7 Chung San South Road, Taipei City, Taiwan. tftsai@yahoo.com. AD - Department of Dermatology, National Taiwan University College of Medicine, Taipei City, Taiwan. tftsai@yahoo.com. LA - eng PT - Journal Article PT - Review DEP - 20210118 PL - New Zealand TA - Am J Clin Dermatol JT - American journal of clinical dermatology JID - 100895290 RN - 0 (HLA-C Antigens) RN - 0 (HLA-C*06 antigen) RN - 0 (HLA-Cw1 antigen) SB - IM MH - Alleles MH - Arthritis, Psoriatic/diagnosis/epidemiology/*genetics/immunology MH - Asian People/genetics MH - Comorbidity MH - Gene Frequency MH - Genetic Predisposition to Disease MH - Genetic Variation/immunology MH - HLA-C Antigens/genetics/*immunology MH - Humans MH - Killer Cells, Natural/immunology MH - Psoriasis/diagnosis/epidemiology/*genetics/immunology MH - Severity of Illness Index MH - Skin/immunology/pathology MH - Virus Diseases/epidemiology/*immunology PMC - PMC7812566 COIS- Yi-Wei Huang has no conflicts of interest that are directly relevant to the content of this article. Tsen-Fang Tsai has conducted clinical trials or received honoraria for serving as a consultant for Abbvie, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galderma, Janssen-Cilag, Merck Sharp & Dohme, Novartis International AG, Pfizer Inc., and UCB Pharma. EDAT- 2021/01/19 06:00 MHDA- 2021/08/24 06:00 PMCR- 2021/01/18 CRDT- 2021/01/18 12:18 PHST- 2020/12/27 00:00 [accepted] PHST- 2021/01/19 06:00 [pubmed] PHST- 2021/08/24 06:00 [medline] PHST- 2021/01/18 12:18 [entrez] PHST- 2021/01/18 00:00 [pmc-release] AID - 10.1007/s40257-020-00585-1 [pii] AID - 585 [pii] AID - 10.1007/s40257-020-00585-1 [doi] PST - ppublish SO - Am J Clin Dermatol. 2021 May;22(3):339-347. doi: 10.1007/s40257-020-00585-1. Epub 2021 Jan 18.